STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
Article Sidebar
Main Article Content
Abstract
According to the Algorithms for specialized care for patients with diabetes mellitus (2019), patients with type 2 diabetes and ASCVD are recommended to use iSGLT2 or glucagon-like peptide-1 receptor agonists, which have proven cardiovascular benefits, as part of hypoglycemic therapy. The study involved 42 patients with type 2 diabetes mellitus, including 21 women and 21 men, who sought advice from the 2nd therapy department at the multidisciplinary clinic of the Tashkent Medical Academy. The duration of the disease ranged from 3 to 8 years, the mean age was 56.6±9.8 years. These patients were divided into 2 groups: group 1 - 18 patients, gliclazide MB with slow release at a dose of 60 mg/day was added to metformin, group 2 included 24 patients, they were added to metformin at a dose of empagliflozin at a dose of 10 mg per day. The results showed a good hypoglycemic effect of empagliflozin with metformin compared with the control group. The drug empagliflozin has a positive effect on heart function, as evidenced by a slight increase in EF.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й вып. (доп.). М.; 2021. [Standards of specialized diabetes care. Eds.: Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition (revised). М.; 2021 (in Russ.). DOI: 10.14341/DM12802.
American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B. et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–S143. DOI: 10.2337/dc22-S009.
Бондаренко И.З., Бубнова М.Г. Что нового появилось в лечении пациента с сахарным диабетом и сердечно-сосудистыми заболеваниями: взгляд кардиологов. CardioСоматика. 2018; 9 (2): 24–30. DOI: 10.26442/2221- 7185_2018.2.24-30
Сергиенко И. В., Аншелес А. А., Халимов Ю. Ш., Шестакова М. В., Бойцов С. А. К21 КАРДИОЛОГИЧЕСКИЕ АСПЕКТЫ САХАРНОГО ДИАБЕТА 2 ТИПА. – Москва: Издательство «Перо», 2018 – 68 с.
Пьяных О.П. Многофакторное управление сахарным диабетом 2 типа у пациентов с очень высоким сердечно-сосудистым риском // Эндокринология: новости, мнения, обучение. 2021. Т. 10, № 3. C. 75–81. DOI: https://doi. org/10.33029/2304-9529-2021- 10-3-75-81
Cherney D.Z., Perkins B.A., Soleymanlou N. et al. Renal hemodynamic effect of sodium-glucose cotransporte r 2 inhibition in patients with type 1 diabetes mellitus // Circulation. 2014. Vol. 129. P. 587–597
Inzucchi S.E., Zinman B., Fitchett D. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of theEMPA-REG OUTCOME trial // Diabetes Care. 2018. Vol. 41. P
IDF Diabetes Atlas. 9th edition. 2019. (Electronic resource.) URL: https://diabetesatlas.org/atlas/ninth-edition/ (access date: 21.01.2022).
Inzucchi S.E., Khunti K., Fitchett D.H., et al. 19-LB: consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME. Diabetes. 2019; 68 (1).
Zinman B., Wanner C., Lachin J.M., et al. Empaglifl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28.
HammoudiN, JeongD, SinghR, FarhatA, KomajdaM, MayouxE, HajjarR, LebecheD. Empagliflozin improves left ventricular diastolic dysfunction in agenetic model of type 2 diabetes. Cardiovascular Drugs and Therapy. 2017;31(3):233-246.]
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovascular Diabetology. 2017;16(1):9
Rawshani A., Rawshani A., Franzén S., et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017; 376: 1407–18.
Эмпаглифлозин как новая стратегия ведения пациентов с сахарным диабетом 2 типа март 2017 г.Сахарный диабет 19(6):494